Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-06-25
2009-12-01
Jiang, Dong (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S350000, C530S387900, C530S388100
Reexamination Certificate
active
07625710
ABSTRACT:
2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.
REFERENCES:
patent: 5488032 (1996-01-01), Dower et al.
patent: 6326472 (2001-12-01), Timans et al.
patent: 6492496 (2002-12-01), Parnet et al.
Reznikov et al. IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. 2000, Proc. Natl. Acad. Sci. USA, 97(5):2174-9.
Norbert W. Tietz, Ph.D., “7-Lipids, Lipoproteins, and Apolipoproteins,”Textbook of Clinical Chemistryp. 842.
Isselbacher et al., “Eicosanoids and Human Disease,”Harrison's Principles of Internal Medicine, 1(13):433-435.
Baum et al., “Molecular characterizastion of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34,”The EMBO Journal, 13(17):3992-4001, 1994.
Bergers et al, “Alternative promoter usage of the Fos-responsive gene Fit-1 generated mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor,”EMBO Journal, 13(5):1176-1188, 1994.
Hashimoto et al., “TheTollGene of Drosophila, Required for Dorsal-Ventral Embryonic Polarity, Appears to Encode a Transmembrane Protein,”Cell, 52:269-27, Jan. 29, 1988.
Arend et al., “Binding of IL-α, I-IL-β, and IL-1 Receptor Antagonist by Soluble IL-1 Receptors and Levels of Soluble IL-1 Receptors in Synovial Fluids,”The Journal of Immunology, 153(10):4767-4774, Nov. 15, 1994.
Jean Marx, “How the Glucocorticoids Suppress Immunity,”Science, 270:232-233, Oct. 13, 1995.
Auphan et al., “Immunosuppresslon by Glucocorticoids: Inhibition of NF-kB Activity Through Induction of IkB Synthesis,”Science, 270:286-290, Oct. 13, 1995.
Howard et al., “Soluble tumor necrosis factor receptor: Inhibition of human immunodeficiency virus activation,”Proc. Natl. Acad Sci. USA, p. 2335, Mar. 1993.
Yamamoto et al,, “Transcriptional Roles of Nuclear Factor kB and Nuclear Factor-Interleukin-6 in the Tumor Necrosis Factor α-Dependent Induction of Cyclooxygenase-2 in MC3T3-E1 Cells,”Journal of Biological Chemistry, 270(52):31315-31320, 1995.
Weih et al., “Multiorgan Inflammation and Hematopoietic Abnormalities in Mice with a Targeted Disruption of ReIB, a Member of the NF-kB/Rel Family,”Cell, 80:331-340, Jan. 27, 1995.
Sha et al., “Targeted Disruption of the p50 Subunit of NF-kB Leads to Multifocal Defects in Immune Responses,”Cell, 80:321-330, Jan. 27, 1995.
Thanos et al, NF-kB: A Lesson in Family Values,Cell, 80:529-532, Feb. 24, 1995.
Carter et al., “Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein,”Nature, 344:633-637, Apr. 12, 1990.
Nomura et al., Prediction of the Coding Sequences of Unidentified Human Genes. I. The Coding Sequences of 40 New Genes (KIAA0001-KIAA0040) Deduced by Analysis of Randomly Sampled cDNA Clones from Human Immature Myeloid Cell Line KG-1,DNA Research, 1:27-35, 1994.
Lord et al., “Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6,”Oncogene, 5(7): 1095-1097, Jul. 1990.
Greenfeder et al., “Molecular Cloning and Characterization of a Second Subunit of the Interleukin I Receptor Complex,”The Journal of Biological Chemistry, 270(23):13757-3765, 1995.
Sims et al., “Geonomic Organization of the Type I and Type II IL-1 Receptors,”Cytokine, 7(6):483-490, Aug. 1995.
Price et al., “Pathophysiology Clinical Concepts of Disease Processes,” p. 36-38, 1986.
Crowell et al., “Functional Bower Disorders and Dysmenorrhea: Don't Cramp My Style,”Gastroenterology, 109(3):1017-1019 Sep. 1995.
Charles A. Dinarello, “Interleukin-1 and Its Biologically Related Cytokines,”Advances in Immunology, 44:153-205, 1989.
William P. Arend, “Interleukin-1 Receptor Antagonist,”Advances in Immunology, 54:167-227, Jan. 19, 1993.
Parnet et al., “A Novel Receptor Similar to the Type I interleukin I Receptor and T1/ST2,” Poster presented at Lake George, NY, Oct. 1995.
Rosenberg et al., Immunopathogenesis of HIV Infection,FASEB Journal. 5: p. 2384, Jul. 1991.
Anthony S. Fauci, :Multifactorial Nature of Human Immunodeficiency Virus Disease: Implications for Therapy,Science, 262:1011-1014, Nov. 12, 1993.
Buckler et al. “Two-step stimulation of B lymphocytes to enter DNA synthesis: synergy between anti-immunoglobulin antibody and cytochalasin on expression of c-myc and a G1-specific gene,”Mol. Cell Biol., 8(3):1371-1375 (abstract only), 1988.
Torigoe et al., “Purification and characterization of the human interleukin-18 receptor,”J. Biol. Chem. And Mole. Biol., 272(41):25737-24742, 1997.
Parnet Patricia
Sims John E.
Immunex Corporation
Jiang Dong
Wiona Thomas J.
LandOfFree
Methods for determining 2F1-binding compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for determining 2F1-binding compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for determining 2F1-binding compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4054823